Siga Technologies Drug Patent Portfolio
Siga Technologies owns 1 orange book drug protected by 10 US patents Given below is the list of Siga Technologies's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11890270 | Polymorphic forms of ST-246 and methods of preparation | 08 Aug, 2032 | Active |
US7737168 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | 04 Sep, 2031 | Active |
US10576165 | ST-246 liquid formulations and methods | 02 Aug, 2031 | Active |
US9233097 | ST-246 liquid formulations | 02 Aug, 2031 | Active |
US9907859 | ST-246 liquid formulations and methods | 02 Aug, 2031 | Active |
US9339466 | Polymorphic forms of ST-246 and methods of preparation | 23 Mar, 2031 | Active |
US8039504 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | 23 Jul, 2027 | Active |
US8124643 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | 18 Jun, 2024 | Expired |
US8530509 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | 18 Jun, 2024 | Expired |
US8802714 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | 18 Jun, 2024 | Expired |
Latest Legal Activities on Siga Technologies's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Siga Technologies.
Activity | Date | Patent Number |
---|---|---|
Recordation of Patent Grant Mailed
Critical
| 06 Feb, 2024 | US11890270 |
Patent Issue Date Used in PTA Calculation
Critical
| 06 Feb, 2024 | US11890270 |
Mail Patent eGrant Notification | 06 Feb, 2024 | US11890270 |
Patent eGrant Notification | 06 Feb, 2024 | US11890270 |
Recordation of Patent eGrant | 06 Feb, 2024 | US11890270 |
Email Notification
Critical
| 06 Feb, 2024 | US11890270 |
Email Notification
Critical
| 18 Jan, 2024 | US11890270 |
Issue Notification Mailed
Critical
| 17 Jan, 2024 | US11890270 |
Dispatch to FDC | 21 Dec, 2023 | US11890270 |
Application Is Considered Ready for Issue
Critical
| 21 Dec, 2023 | US11890270 |
Issue Fee Payment Received
Critical
| 19 Dec, 2023 | US11890270 |
Issue Fee Payment Verified
Critical
| 19 Dec, 2023 | US11890270 |
Payment of Maintenance Fee, 8th Yr, Small Entity | 17 Nov, 2023 | US9339466 |
Mail Notice of Allowance
Critical
| 29 Sep, 2023 | US11890270 |
Notice of Allowance Data Verification Completed
Critical
| 26 Sep, 2023 | US11890270 |
Siga Technologies's Family Patents
Siga Technologies drugs have patent protection in a total of 22 countries. It's US patent count contributes only to 27.3% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Siga Technologies Drug List
Given below is the complete list of Siga Technologies's drugs and the patents protecting them.
1. Tpoxx
Tpoxx is protected by 10 patents, out of which 3 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11890270 | Polymorphic forms of ST-246 and methods of preparation |
08 Aug, 2032
(7 years from now)
| Active |
US7737168 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
04 Sep, 2031
(6 years from now)
| Active |
US10576165 | ST-246 liquid formulations and methods |
02 Aug, 2031
(6 years from now)
| Active |
US9233097 | ST-246 liquid formulations |
02 Aug, 2031
(6 years from now)
| Active |
US9907859 | ST-246 liquid formulations and methods |
02 Aug, 2031
(6 years from now)
| Active |
US9339466 | Polymorphic forms of ST-246 and methods of preparation |
23 Mar, 2031
(6 years from now)
| Active |
US8039504 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
23 Jul, 2027
(2 years from now)
| Active |
US8124643 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
18 Jun, 2024
(3 months ago)
| Expired |
US8530509 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
18 Jun, 2024
(3 months ago)
| Expired |
US8802714 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
18 Jun, 2024
(3 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tpoxx's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List